摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

7-chloro-6-methyl-1-(4'-methylbenzyl)-1,4-dihydro-indeno[1,2-c]pyrazole-3-carboxylic acid | 1240996-40-0

中文名称
——
中文别名
——
英文名称
7-chloro-6-methyl-1-(4'-methylbenzyl)-1,4-dihydro-indeno[1,2-c]pyrazole-3-carboxylic acid
英文别名
7-chloro-6-methyl-1-[(4-methylphenyl)methyl]-4H-indeno[1,2-c]pyrazole-3-carboxylic acid
7-chloro-6-methyl-1-(4'-methylbenzyl)-1,4-dihydro-indeno[1,2-c]pyrazole-3-carboxylic acid化学式
CAS
1240996-40-0
化学式
C20H17ClN2O2
mdl
——
分子量
352.82
InChiKey
ZSHMZVDNERNMSS-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4.7
  • 重原子数:
    25
  • 可旋转键数:
    3
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.2
  • 拓扑面积:
    55.1
  • 氢给体数:
    1
  • 氢受体数:
    3

文献信息

  • PHARMACEUTICAL COMPOSITIONS
    申请人:LAZZARI Paolo
    公开号:US20100216785A1
    公开(公告)日:2010-08-26
    Microemulsions of pharmaceutical compositions comprising, the following components (% by weight), the sum of the components being 100%: S) from 0.01 to 95% of one or more compounds selected from surfactants, polymers, forming organized structures as: aggregates, micelles, liquid crystals, vesicles, in the liquid in which they are solubilized, O) from 0.01 to 95% of one or more oils selected from esters of C 4 -C 32 acids or C 4 -C 32 acids, PA) from 0.001 to 90% of compounds having affinity for the CB1 and/or CB2 cannabinoidergic receptors of formula A′: AD) from 0 to 60% by weight of one or more compounds selected from modifiers of the water and/or oil polarity, modifiers of the film curvature of component S), co-surfactants, water or a saline aqueous solution the difference to 100%, wherein the ratio by weight S)/PA) is lower than that of microemulsions wherein component O) is absent.
    药物组成的微乳液包含以下组分(按重量百分比计算),各组分总和为100%:S)从0.01到95%的一种或多种化合物,选自表面活性剂、聚合物,形成有序结构,如:聚集体、胶束、液晶、囊泡,在它们被溶解的液体中,O)从0.01到95%的一种或多种油,选自C4-C32酸酯或C4-C32酸,PA)从0.001到90%的化合物,具有亲和力为公式A'的CB1和/或CB2大麻素受体,AD)从0到60%的一种或多种化合物,按重量计算,选自调节剂,和/或油极性的调节剂,组分S)的膜曲率调节剂,共表面活性剂,或盐溶液之差为100%,其中按重量比S)/PA)低于不含组分O)的微乳液的比例。
  • Tricyclic condensed pyrazole derivatives as CB1 inhibitors
    申请人:Neuroscienze Pharmaness S.C. A R.L.
    公开号:EP2223914A1
    公开(公告)日:2010-09-01
    Condensed tricyclic compounds having a condensed structure containing one phenyl and one pyrazole ring linked with each other by a central ring rcomprising from five to eight atoms, having affinity for the CB1 and/or CB2 receptors, with central nervous system and/or peripheral activity, of formula (I) : wherein the various substituents are as defined in the description. The compounds show affinity for the CB1 and/or CB2 cannabinoidergic receptors.
    具有紧凑结构的三环化合物,其中包含一个苯环和一个吡唑环,通过一个含有五至八个原子的中心环相互连接,具有对CB1和/或CB2受体的亲和力,具有中枢神经系统和/或外周活性,化学式为(I):其中各种取代基如描述中定义。这些化合物显示对CB1和/或CB2大麻素受体的亲和力。
  • PHARMACEUTICAL COMPOUNDS
    申请人:LAZZARI Paolo
    公开号:US20100215741A1
    公开(公告)日:2010-08-26
    Condensed tricyclic compounds having a condensed structure containing one phenyl and one pyrazole ring linked with each other by a central ring comprising from five to eight atoms, having affinity for the CB1 and/or CB2 receptors, with central nervous system and/or peripheral activity, of formula (I): wherein the various substituents are as defined in the description. The compounds show affinity for the CB1 and/or CB2 cannabinoidergic receptors.
    具有紧凑结构的三环化合物,包含一个苯环和一个吡唑环,通过一个由五至八个原子组成的中心环相互连接,在CB1和/或CB2受体上具有亲和力,具有中枢神经系统和/或外周活性,化学式(I)如下:其中各种取代基如描述中所定义。这些化合物对CB1和/或CB2类大麻素受体具有亲和力。
  • Tricyclic pyrazole derivatives and microemulsions thereof as CB1- and/or CB2-inhibitors
    申请人:Neuroscienze Pharmaness S.C. A R.L.
    公开号:EP2223913A1
    公开(公告)日:2010-09-01
    Microemulsions of pharmaceutical compositions comprising the following components (% by weight), the sum of the components being 100%: S) from 0.01 to 95% of one or more compounds selected from surfactants, polymers forming organized structures as: aggregates, micelles, liquid crystals, vesicles, in the liquid in which they are solublized, O) from 0.01 to 95% of one or more oils selected from esters of C4-C32 acids or C4-C32 acids, PA) from 0.001 to 90% of compounds having affinity for the CB1 and/or CB2 cannabinoidergic receptors of formula A': AD) from 0 to 60% by weight of one or more compounds selected from modifiers of the water and/or oil polarity, modifiers of the film curvature of component S), co-surfactants, water or a saline aqueous solution the difference to 100%, wherein the ratio by weight S)/PA) is lower than that of microemulsions wherein component O) is absent.
    医药组合物的微乳液包含以下组分(按重量百分比计),各组分之和为100%:S)从0.01到95%的一种或多种从表面活性剂、形成有序结构的聚合物,如:聚集体、胶束、液晶、囊泡,在它们溶解的液体中选择的化合物,O)从0.01到95%的一种或多种选择自C4-C32酸酯或C4-C32酸的油,PA)从0.001到90%的具有亲和力的化合物CB1和/或CB2大麻素受体的配方A',AD)从0到60%的一种或多种选择自和/或油极性修饰剂,成分S)的膜曲率修饰剂,共表面活性剂,或盐溶液的差异为100%,其中按重量比S)/PA)低于不含成分O)的微乳液。
查看更多